Literature DB >> 18094611

Increased expression of cytoplasmic HuR in familial adenomatous polyposis.

Lodewijk A A Brosens1, Josbert J Keller, Leena Pohjola, Caj Haglund, Folkert H Morsink, Christine Iacobuzio-Donahue, Michael Goggins, Francis M Giardiello, Ari Ristimäki, G Johan A Offerhaus.   

Abstract

BACKGROUND: HuR is an mRNA stability factor that binds to the AU-rich element-containing 3' untranslated region of the transcript. HuR overexpression is associated with increased tumor growth. Increased cytoplasmic HuR expression occurs in several cancer types, including colorectal cancer where it may contribute to the increased cyclooxygenase-2 (COX- 2) expression observed during tumorigenesis. To investigate expression of HuR in the colorectal adenoma-carcinoma sequence, we examined expression of HuR in colorectal mucosa of patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer with correlation to COX-2 expression.
RESULTS: Cytoplasmic HuR staining was found in the epithelium of 10% of normal mucosa, 14.3% of adenomas and 88.9% of adenocarcinomas from FAP patients (p < 0.01) and in 68.8% of sporadic colorectal carcinomas. High epithelial COX-2 immunostaining was observed in 10% of normal, 8% of adenomas and all adenocarcinomas from FAP patients (p < 0.01) and in 69.5% of sporadic colorectal carcinomas. Positive cytoplasmic HuR immunostaining correlated with high COX-2 immunoreactivity in colon mucosa of FAP patients (p < 0.01) and in sporadic colorectal carcinomas. (p = 0.016)
MATERIALS AND METHODS: HuR and COX-2 protein expression were studied by immunohistochemistry of normal colon mucosa (N=20), adenomas (N=112), carcinomas (N=9) from patients with FAP, and 141 sporadic colorectal adenocarcinomas (Dukes B and C).
CONCLUSIONS: HuR is increasingly expressed in the cytoplasmic epithelial compartment in consecutive stages of the adenoma-carcinoma sequence in FAP. Also, COX-2 levels correlate with cytoplasmic expression of HuR in colonic epithelium of FAP patients and in sporadic colorectal cancer specimens. The role of cytoplasmic expression of HuR as a biomarker for progression of adenomas in FAP needs further study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094611     DOI: 10.4161/cbt.7.3.5417

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  14 in total

1.  Myeloid cell expression of the RNA-binding protein HuR protects mice from pathologic inflammation and colorectal carcinogenesis.

Authors:  Anthie Yiakouvaki; Marios Dimitriou; Ioannis Karakasiliotis; Christina Eftychi; Stamatis Theocharis; Dimitris L Kontoyiannis
Journal:  J Clin Invest       Date:  2011-12-27       Impact factor: 14.808

Review 2.  Clinical significance of HuR expression in human malignancy.

Authors:  Ioly Kotta-Loizou; Constantinos Giaginis; Stamatios Theocharis
Journal:  Med Oncol       Date:  2014-08-13       Impact factor: 3.064

3.  Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma.

Authors:  Elizabeth Van Tubergen; Robert Vander Broek; Julia Lee; Gregory Wolf; Thomas Carey; Carol Bradford; Mark Prince; Keith L Kirkwood; Nisha J D'Silva
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

Review 4.  Regulation of tumor suppressor p53 at the RNA level.

Authors:  Anna Vilborg; Margareta T Wilhelm; Klas G Wiman
Journal:  J Mol Med (Berl)       Date:  2010-03-21       Impact factor: 4.599

5.  Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma.

Authors:  Cong Zhang; Guoliang Xue; Jingwang Bi; Ming Geng; Huili Chu; Yaping Guan; Jun Wang; Baocheng Wang
Journal:  Tumour Biol       Date:  2013-07-20

6.  Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice.

Authors:  Durga P Cherukuri; Tomo-O Ishikawa; Patrick Chun; Art Catapang; David Elashoff; Tristan R Grogan; James Bugni; Harvey R Herschman
Journal:  Mol Oncol       Date:  2013-11-08       Impact factor: 6.603

7.  HuR Small-Molecule Inhibitor Elicits Differential Effects in Adenomatosis Polyposis and Colorectal Carcinogenesis.

Authors:  Michaela Lang; David Berry; Katharina Passecker; Ildiko Mesteri; Sabin Bhuju; Florian Ebner; Vitaly Sedlyarov; Rayko Evstatiev; Kyle Dammann; Alexander Loy; Orest Kuzyk; Pavel Kovarik; Vineeta Khare; Martin Beibel; Guglielmo Roma; Nicole Meisner-Kober; Christoph Gasche
Journal:  Cancer Res       Date:  2017-02-20       Impact factor: 12.701

Review 8.  Breast cancer epigenetics: from DNA methylation to microRNAs.

Authors:  Jürgen Veeck; Manel Esteller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-01-27       Impact factor: 2.673

Review 9.  Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis.

Authors:  Jun Wang; Yan Guo; Huili Chu; Yaping Guan; Jingwang Bi; Baocheng Wang
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

10.  The RNA-binding protein HuR regulates DNA methylation through stabilization of DNMT3b mRNA.

Authors:  Isabel López de Silanes; Myriam Gorospe; Hiroaki Taniguchi; Kotb Abdelmohsen; Subramanya Srikantan; Miguel Alaminos; María Berdasco; Rocío G Urdinguio; Mario F Fraga; Filipe V Jacinto; Manel Esteller
Journal:  Nucleic Acids Res       Date:  2009-03-06       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.